Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Asceniv PK, Efficacy and Safety in Pediatric PIDD
NCT05070455Phase 4Unknown
- Sponsor
- ADMA Biologics, Inc.
- Start
- Sep 2022
- Primary completion
- Mar 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of immune globulin intravenous, human-slra in primary immunodeficiency disease (PID), sponsored by ADMA Biologics, Inc.. Status: unknown.
02
Drugs
immune globulin intravenous, human-slra
03
Conditions
primary immunodeficiency disease (PID)
Beyond the preview
Go deeper on NCT05070455.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05070455.